Impact of diabetes in patients waiting for invasive cardiac procedures during COVID-19 pandemic

Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Moreno, R
- Diarte, JA
- Salinas, P
- Hernandez, JMD
- Andres-Cordon, JF
- Trillo, R
- Briales, JA
- Amat-Santos, I
- Romaguera, R
- Diaz, JF
- Vaquerizo, B
- Ojeda, S
- Cruz-Gonzalez, I
- Morena-Salas, D
- de Prado, AP
- Sarnago, F
- Portero, P
- Gutierrez-Barrios, A
- Alfonso, F
- Bosch, E
- Pinar, E
- Ruiz-Arroyo, JR
- Ruiz-Quevedo, V
- Jimenez-Mazuecos, J
- Lozano, F
- Rumoroso, JR
- Novo, E
- Irazusta, FJ
- Del Blanco, BG
- Moreu, J
- Ballesteros-Pradas, SM
- Frutos, A
- Villa, M
- Alegria-Barrero, E
- Lazaro, R
- Paredes, E
Grupos
Abstract
Background During COVID-19 pandemic, elective invasive cardiac procedures (ICP) have been frequently cancelled or postponed. Consequences may be more evident in patients with diabetes. Objectives The objective was to identify the peculiarities of patients with DM among those in whom ICP were cancelled or postponed due to the COVID-19 pandemic, as well as to identify subgroups in which the influence of DM has higher impact on the clinical outcome. Methods We included 2,158 patients in whom an elective ICP was cancelled or postponed during COVID-19 pandemic in 37 hospitals in Spain. Among them, 700 (32.4%) were diabetics. Patients with and without diabetes were compared. Results Patients with diabetes were older and had a higher prevalence of other cardiovascular risk factors, previous cardiovascular history and co-morbidities. Diabetics had a higher mortality (3.0% vs. 1.0%; p = 0.001) and cardiovascular mortality (1.9% vs. 0.4%; p = 0.001). Differences were especially important in patients with valvular heart disease (mortality 6.9% vs 1.7% [p < 0.001] and cardiovascular mortality 4.9% vs 0.9% [p = 0.002] in patients with and without diabetes, respectively). In the multivariable analysis, diabetes remained as an independent risk factor both for overall and cardiovascular mortality. No significant interaction was found with other clinical variables. Conclusion Among patients in whom an elective invasive cardiac procedure is cancelled or postponed during COVID-19 pandemic, mortality and cardiovascular mortality is higher in patients with diabetes, irrespectively on other clinical conditions. These procedures should not be cancelled in patients with diabetes.
Datos de la publicación
- ISSN/ISSNe:
- 1475-2840, 1475-2840
- Tipo:
- Article
- Páginas:
- 69-69
- Factor de Impacto:
- 2,449 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
CARDIOVASCULAR DIABETOLOGY BioMed Central
Citas Recibidas en Web of Science: 3
Documentos
- No hay documentos
Filiaciones
Keywords
- Diabetes; Interventional cardiology; COVID-19; Mortality; Waiting list
Proyectos asociados
PREMICAT. DESARROLO DE UNA ESTRATEGIA PARA LA PREVENCION MIOCARDICA DEL DAÑO INDUCIDO POR REPERFUSION BASADA EN EL USO DE CATETERES Y POLIMEROS TARAPEUTICOS DE NUEVA GENERACION.
Investigador Principal: PILAR SEPÚLVEDA SANCHIS
DTS15/00079 . INSTITUTO DE SALUD CARLOS III . 2016
RED DE TERAPIA CELULAR (TERCEL).
Investigador Principal: PILAR SEPÚLVEDA SANCHIS
RD16/0011/0004 . INSTITUTO DE SALUD CARLOS III . 2017
INCORPORACIÓN GRUPOS CIBER. DR. DOLZ
Investigador Principal: LUIS VICENTE MARTÍNEZ DOLZ
CB16/11/00261 . INSTITUTO DE SALUD CARLOS III . 2017
Generation of a biological product based on angiogenic extracellular vesicles from genetically modified mesenchymal stem cells for the treatment of cardio-vascular diseases (gevecar).
Investigador Principal: PILAR SEPÚLVEDA SANCHIS
PI19/00245 . INSTITUTO DE SALUD CARLOS III . 2020
ENSAYO MULTICENTRICO, ALEATORIZADO, DOBLE CIEGO, COMPARADO CON PLACEBO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DEL TRATAMIENTO CON UN INHIBIDOR DE LA QUIMASA (BAY 1142524), A UNA DOSIS ORAL DE 25 MG BID DURANTE 6 MESES ANADIDO AL TRATAMIENTO ESTANDAR EN PACIENTES CON INFARTO AGUDO DE MIOCARDIO Y REDUCCION DE LA FRACCION DE EYECCION DEL VENTRICULO IZQUIERDO (FEVI . 45%). (CHIARA MIA 2).
Investigador Principal: VICENTE MIRÓ PALAU
BAY1142524/16673 . 2016
REGISTRO MULTICÉNTRICO DE REVASCULARIZACIÓN SECUNDARIA.
Investigador Principal: JOSÉ LUIS DÍEZ GIL
REGISTRO REVASEC . 2018
REGISTRO PROSPECTIVO EN PACIENTES MAYORES DE 75 AÑOS TRATADOS CON STENTS XIENCE SIERRA. ESTUDIO SIERRA 75.
Investigador Principal: JOSÉ LUIS DÍEZ GIL
SIERRA 75 - EPIC05 . 2019
BALÓN LIBERADOR DE PACLITAXEL TRAS STENT CONVENCIONAL VS STENT LIBERADOR DE FÁRMACOS EN EL INFARTO AGUDO CON ELEVACIÓN DE ST (ESTUDIO PEBSI-2).
Investigador Principal: LUIS ANDRÉS LALAGUNA
PEBSI-2 . 2016
FUNCTIONAL VERSUS CULPRIT-ONLY REVASCULARIZATION IN ELDERLY PATIENTS WITH MYOCARDIAL INFARCTION AND MULTIVESSEL DISEASE.
Investigador Principal: JOSÉ LUIS DÍEZ GIL
ESTUDIO FIRE . 2019
CONCORDANCIA ENTRE FFR E IFR PARA LA VALORACIÓN DE LESIONES INTERMEDIAS EN EL TRONCO COMÚN IZQUIERDO. APLICACIÓN PROSPECTIVA DE UN VALOR DE IFR PREDEFINIDO PARA LA VALORACIÓN DE LESIONES INTERMEDIAS EN EL TRONCO COMÚN IZQUIERDO (ESTUDIO ILITRO).
Investigador Principal: JOSÉ LUIS DÍEZ GIL
EPIC-07 . 2019
Cita
Moreno R,Diez JL,Diarte JA,Salinas P,Hernandez JMD,Andres JF,Trillo R,Briales JA,Amat I,Romaguera R,Diaz JF,Vaquerizo B,Ojeda S,Cruz I,Morena D,de Prado AP,Sarnago F,Portero P,Gutierrez A,Alfonso F,Bosch E,Pinar E,Ruiz JR,Ruiz V,Jimenez J,Lozano F,Rumoroso JR,Novo E,Irazusta FJ,Del Blanco BG,Moreu J,Ballesteros SM,Frutos A,Villa M,Alegria E,Lazaro R,Paredes E. Impact of diabetes in patients waiting for invasive cardiac procedures during COVID-19 pandemic. Cardiovasc Diabetol. 2021. 20. (1):p. 69-69. IF:8,949. (1).